Exosomics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Investors
-
9
Exosomics General Information
Description
Developer of biotechnology equipment designed to launch a new generation of tests for cancer screening and liquid biopsy. The company provides a range of pre-analytical technologies able to enrich tumor-derived EVs and exosomes from human biofluids and extract their genomic DNA and RNA content, enabling patients to get reliable and cost-effective treatments against cancer.
Contact Information
Website
www.exosomics.euCorporate Office
- Via Fiorentina, 1
- 53100 Siena
- Italy
Corporate Office
- Via Fiorentina, 1
- 53100 Siena
- Italy
Exosomics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 17-May-2017 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Exosomics Patents
Exosomics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018234463-A1 | Methods and kits relating to the capture of ca-ix positive exosomes | Inactive | 21-Jun-2017 | ||
| ES-2700404-T3 | Use of tm9sf4 as a biomarker for exosomes associated with tumors | Active | 06-Jun-2014 | ||
| EP-3152576-A2 | Use of tm9sf4 as a biomarker for tumor associated exosomes | Active | 06-Jun-2014 | ||
| EP-3152576-B1 | Use of tm9sf4 as a biomarker for tumor associated exosomes | Active | 06-Jun-2014 | ||
| US-20220349892-A1 | Use of tm9sf4 as a biomarker for tumor associated exosomes | Inactive | 06-Jun-2014 | G01N33/5759 |
Exosomics Signals
Exosomics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Agilent Technologies | Corporation | Minority | ||
| Biobalt Holding | Corporation | Minority | ||
| Black Swan Trade | Corporation | Minority | ||
| FinBiotech | Venture Capital | Minority | ||
| HansaBioMed Life Sciences | Corporation | Minority |
Exosomics Investments & Acquisitions (2)
Exosomics’s most recent deal was a Merger/Acquisition with Longevity Bioscience for . The deal was made on 31-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Longevity Bioscience | 31-Jul-2025 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Longevity Bioscience | 03-Sep-2024 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Exosomics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Longevity Bioscience | Siena, Italy | 2024 |
Exosomics FAQs
-
When was Exosomics founded?
Exosomics was founded in 2011.
-
Where is Exosomics headquartered?
Exosomics is headquartered in Siena, Italy.
-
What is the size of Exosomics?
Exosomics has 9 total employees.
-
What industry is Exosomics in?
Exosomics’s primary industry is Diagnostic Equipment.
-
Is Exosomics a private or public company?
Exosomics is a Private company.
-
What is Exosomics’s current revenue?
The current revenue for Exosomics is .
-
Who are Exosomics’s investors?
Agilent Technologies, Biobalt Holding, Black Swan Trade, FinBiotech, and HansaBioMed Life Sciences are 5 of 9 investors who have invested in Exosomics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process